In:
American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology (ASCO), , No. 33 ( 2013-05), p. 257-263
Abstract:
KEYPOINTS Fusion oncogenes are key events in the molecular pathogenesis of major salivary gland carcinomas and may contribute as diagnostic and prognostic biomarkers. These fusion oncogenes encode transcriptional coactivators, tyrosine kinase receptors, and transcription factors involved in growth factor signaling and cell-cycle regulation, and may provide customized molecular targets for therapy. Currently, radiation plays an important role in the postoperative and definitive setting for malignant salivary gland tumors, with multiple retrospective reports indicating improved outcomes for patients with high-risk features. Risk factors for recurrence postoperatively include locally advanced tumor, pathologic T3 to T4 stage, invasion into adjacent structures, nodal involvement, high-grade histology, perineural invasion, angiolymphatic invasion, positive margins, and recurrent disease. In the past, systemic treatment was reserved for the palliative setting; however, platinum-based chemotherapy is currently under investigation in association with postoperative radiotherapy in an effort to improve overall outcomes for locally advanced, high-risk tumors. Molecular driven therapies remain investigational and prognostic as well as predictive; biomarkers are needed to advance therapeutic approaches for salivary gland cancers.
Type of Medium:
Online Resource
ISSN:
1548-8748
,
1548-8756
DOI:
10.14694/EdBook_AM.2013.33.257
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2013
detail.hit.zdb_id:
2431126-1
Permalink